Mga Batayang Estadistika
| LEI | 894500LSC3H1WGG6LV25 |
| CIK | 1534248 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Chemomab Therapeutics Ltd. - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) 6 Habarzel Street, Building C, 10th Floor, Tel-Aviv, Israel (Address of p |
|
| August 14, 2025 |
Exhibit 99.2 CHEMOMAB THERAPEUTICS LTD. CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS This Report on Form 6-K contains forward-looking statements. All statements other than statements of historical fact are “forward-looking statements” for purposes of this Report on Form 6-K. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, per |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) 6 Habarzel Street, Building C, 10th Floor, Tel-Aviv, Israel (Address of p |
|
| August 14, 2025 |
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update Exhibit 99.3 Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update —Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program— —Phase 2 SPRING Trial Data Highlighting Nebokitug’s Unique Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in PSC Featured at Multiple Maj |
|
| August 14, 2025 |
Exhibit 99.1 Chemomab Therapeutics Ltd. and its subsidiaries Interim Condensed Consolidated Financial Statements As of June 30, 2025 (Unaudited) Chemomab Therapeutics Ltd. and its subsidiaries Interim Condensed Consolidated Financial Statements as of June 30, 2025 (Unaudited) Contents Page Interim Condensed Consolidated Balance Sheets 3 Interim Condensed Consolidated Statements of Operations 4 Int |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-38807 CHEMOMAB THERAPEUTICS LTD. Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executive office) Indicate by check mark whether the reg |
|
| July 25, 2025 |
Exhibit 10.1 Chemomab Therapeutics Ltd. American Depositary Shares Each Representing 20 Ordinary Shares (no par value) Sales Agreement July 25, 2025 LifeSci Capital, LLC 1700 Broadway, 40th Floor New York, NY 10019 Ladies and Gentlemen: Chemomab Therapeutics Ltd., a company organized under the laws of Israel (the “Company”), confirms its agreement (this “Agreement”) with LifeSci Capital, LLC (the |
|
| July 25, 2025 |
CHEMOMAB THERAPEUTICS LTD. Up to $7,258,687 American Depositary Shares representing Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration Statement No. 333- 275002 PROSPECTUS SUPPLEMENT (To Prospectus dated November 3, 2023) CHEMOMAB THERAPEUTICS LTD. Up to $7,258,687 American Depositary Shares representing Ordinary Shares We have entered into a Sales Agreement, dated as of July 25, 2025 (the “Sales Agreement”) with LifeSci Capital LLC (the “Agent”) relating to American Depositary Shares |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executive |
|
| May 27, 2025 |
Annual General Meeting of Chemomab Therapeutics Ltd. Exhibit 99.2 Annual General Meeting of Chemomab Therapeutics Ltd. Date: July 1, 2025 See Voting Instruction On Reverse Side. Please make your marks like this: ☒ Use dark black pencil or pen only For Against Abstain 1. To re-elect each of Dr. Nissim Darvish and Ms. Jill Quigley as Class I directors, to hold office until the close of the Company’s annual general meeting of shareholders in 2028, and |
|
| May 27, 2025 |
Exhibit 99.1 May 27, 2025 Dear Chemomab Therapeutics Ltd. Shareholders: We cordially invite you to attend the Annual General Meeting of Shareholders (the “Meeting”) of Chemomab Therapeutics Ltd. (the “Company”), to be held on July 1, 2025, at 4.30 p.m. (Israel time), at Meitar | Law Offices, located at 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel. The Company’s notice of the Meeting, |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executive |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executive |
|
| May 15, 2025 |
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update Exhibit 99.1 Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update —Reported Positive 48-Week Data from SPRING Trial—Nebokitug Treatment in PSC Patients with Moderate/Advanced Disease Resulted in Continued Improvements across Key Biomarkers of Liver Injury, Inflammation and Fibrosis— —Aligned with FDA on Pathway to Potential Regulatory Approval for the |
|
| April 15, 2025 |
Exhibit 99.1 Chemomab Announces New Medical and Clinical Appointments David M. Weiner, MD, Rejoins Chemomab as Interim Chief Medical Officer, Bringing Extensive Biotechnology and Pharmaceutical Industry R&D, Drug Development and Strategic Experience Jack Lawler, Who Oversaw the Conduct of Chemomab’s Successful Phase 2 SPRING Trial in PSC, Assumes Chief Development Officer Role TEL AVIV, Israel, Ap |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executiv |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SE |
|
| April 4, 2025 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14a OF THE SECURITIES EXCHANGE ACT OF 1934 AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002 I, Adi Mor, certify that: 1. I have reviewed this Annual Report on Form 20-F of Chemomab Therapeutics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mater |
|
| April 4, 2025 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14a OF THE SECURITIES EXCHANGE ACT OF 1934 AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002 I, Sigal Fattal, certify that: 1. I have reviewed this Annual Report on Form 20-F of Chemomab Therapeutics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a |
|
| April 4, 2025 |
Exhibit 11.1 Chemomab Therapeutics Ltd. Insider Trading and Blackout Policy Adopted by the Board of Directors on November 14, 2019, as amended on April 3, 2025 POLICY STATEMENT This document sets forth the policies of Chemomab Therapeutics Ltd. (the “Company”) prohibiting “insider trading” and the procedures to be followed by directors, officers and employees of the Company before engaging in any |
|
| April 4, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm The Board of Directors Chemomab Therapeutics Ltd.: We consent to the incorporation by reference in the registration statement on Form F-3 (No. 333-281750 and No. 333-275002) and registration statements on Form S-8 (No. 333-266868 and No. 333-259489) of our report dated April 4, 2025, with respect to the consolidated financial st |
|
| April 4, 2025 |
Exhibit 13.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Sigal Fattal, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 20-F of Chemomab Therapeutics Ltd. for the fiscal year ended December 31, |
|
| April 4, 2025 |
Exhibit 1.1 THE COMPANIES LAW, 1999 A LIMITED LIABILITY COMPANY - ARTICLES OF ASSOCIATION OF CHEMOMAB THERAPEUTICS LTD. Therapeutics As Amended on June 10, 2024 Preliminary 1. Definitions; Interpretation. (a) In these Articles, the following terms (whether or not capitalized) shall bear the meanings set forth opposite them, respectively, unless the subject or context requires otherwise. “Articles” |
|
| April 4, 2025 |
Exhibit 13.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Adi Mor, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 20-F of Chemomab Therapeutics Ltd. for the fiscal year ended December 31, 2024 |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executiv |
|
| March 27, 2025 |
Exhibit 99.1 Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers Reinforces potential of nebokitug to become the first approved drug with disease-modifying activity for PSC-a deadly disorder that currently has no effective treatments Treatment in PSC patients with moderate/advanced diseas |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: March 2025 Commission File Number: 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal execut |
|
| March 3, 2025 |
Exhibit 99.1 Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update ─Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)─ ─Achieved Alignment with FDA on Clear and Efficient Pathway to Potential Regulatory Approval for the Treatment of PSC with N |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executiv |
|
| February 19, 2025 |
Exhibit 99.1 Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis Single Positive Phase 3 Trial Designed to Support Full Regulatory Approval, For the First Time Providing Regulatory Clarity in PSC and Positioning Nebokitug to Potentially Become the First FDA-App |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal execu |
|
| December 2, 2024 |
As filed with the Securities and Exchange Commission on [ ], 2024 As filed with the Securities and Exchange Commission on [ ], 2024 Registration No. |
|
| December 2, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES (1)(2) POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 ON FORM F-3 (Form Type) Chemomab Therapeutics Ltd. (Exact Name of registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (3) Proposed Maximum Offering Price per Unit Maximum |
|
| November 29, 2024 |
SC 13D/A 1 zk2432412.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 240.13d-2(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) (Amendment No. 2)* Chemomab Therapeutics Ltd. (Name of Issuer) American Depositary Shares, each of which represents twenty Ordi |
|
| November 21, 2024 |
SC 13G 1 CMMB13g.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT N0. 1) Chemomab Therapeutics Ltd. (Name of Issuer) American Depository Shares, each of which represent twenty ordinary shares, no par value (Title of Class of Securities) 16385C104 (CUSIP Number) November 21, 2024 (Date of Event Which Requires |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal execu |
|
| November 15, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-275002 PROSPECTUS SUPPLEMENT (To Prospectus dated November 3, 2023) Up to $8,626,564 American Depositary Shares This prospectus supplement amends and supplements the information in the prospectus supplement, dated November 3, 2023, filed as a part of our registration statement on Form F-3 (File No. 333-275002), or the Prior Prospectus. This pro |
|
| November 14, 2024 |
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update ──FDA End-of-Phase 2 Meeting Scheduled in Fourth Quarter 2024 to Discuss the Design of a CM-101 Accelerated Approval Phase 3 Trial in Primary Sclerosing Cholangitis (PSC)── ──Cash Runway Extended to Early 2026; Continuing Discussions with Potential Strategic Partners; Preparations Underw |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal execu |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal execut |
|
| October 11, 2024 |
Exhibit 99.1 October 11, 2024 Dear Chemomab Therapeutics Ltd. Shareholders: We cordially invite you to attend a Special General Meeting of Shareholders (the “Meeting”) of Chemomab Therapeutics Ltd. (the “Company”), to be held on November 18, 2024, at 4.30 p.m. (Israel time), at Meitar | Law Offices, located at 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel. The Company’s notice of the |
|
| October 11, 2024 |
Special General Meeting of Chemomab Therapeutics Ltd. Exhibit 99.2 Special General Meeting of Chemomab Therapeutics Ltd. Date: November 18, 2024 See Voting Instruction On Reverse Side. Please make your marks like this: ☒ Use dark black pencil or pen only For Against Abstain 1. To approve the grant of 126,848 restricted share units to Dr. Adi Mor, as detailed in the Proxy Statement, dated October 11, 2024. ☐ ☐ ☐ Authorized Signatures - This section mu |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Chemomab Therapeutics Ltd. (Name of Issuer) Ordinary Shares, no par value American Depository Shares, each of which represents twenty Ordinary Shares, no par value (Title of Class of Securities) 16385C104** (CUSIP Number) OrbiMed Israel BioFund GP Limite |
|
| September 16, 2024 |
EX-99.1 2 ss3873211ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 4 to Schedule 13D, dated September 12, 2024 with respect to the Ordinary Shares and American Depository Shares of Chemomab Therapeutics Ltd. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and |
|
| September 9, 2024 |
8,097,167 ADSs Offered by the Selling Shareholders Chemomab Therapeutics Ltd. Filed pursuant to Rule 424(b)(3) Registration No. 333-281750 PROSPECTUS 8,097,167 ADSs Offered by the Selling Shareholders Chemomab Therapeutics Ltd. This prospectus relates to the resale, from time to time, by the selling shareholders identified in this prospectus (“Selling Shareholders”) of 8,097,167 American Depositary Shares (“ADSs”). Each ADS represents twenty (20) of our ordinary shares, no |
|
| September 4, 2024 |
September 4, 2024 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| August 23, 2024 |
As filed with the Securities and Exchange Commission on August 23, 2024 As filed with the Securities and Exchange Commission on August 23, 2024 Registration No. |
|
| August 23, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) Chemomab Therapeutics Ltd. |
|
| August 21, 2024 |
Exhibit 99.2 CHEMOMAB THERAPEUTICS LTD. CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS This Report on Form 6-K contains forward-looking statements. All statements other than statements of historical fact are “forward-looking statements” for purposes of this Report on Form 6-K. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, per |
|
| August 21, 2024 |
Exhibit 99.1 Chemomab Therapeutics Ltd. and its subsidiaries Interim Condensed Consolidated Financial Statements As of June 30, 2024 (Unaudited) Chemomab Therapeutics Ltd. and its subsidiaries Interim Condensed Consolidated Financial Statements as of June 30, 2024 (Unaudited) Contents Page Interim Condensed Consolidated Balance Sheets 3 Interim Condensed Consolidated Statements of Operations 4 Int |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executi |
|
| August 21, 2024 |
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.3 Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update ──Reported Positive Phase 2 Results Demonstrating Safety and Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC)── ──Establishes Clinical Proof-of-Concept for Disease-Modifying Potential of CM-101 and Provides |
|
| August 20, 2024 |
EX-99 2 exhibit1.htm EXHIBIT 1 Exhibit 1 Joint Filing Agreement Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Chemomab Therapeutics Ltd.; each of them is responsible for the |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* Chemomab Therapeutics Ltd. (Name of Issuer) Ordinary shares, no par value American Depository Shares, each of which represents twenty ordinary shares, no par value (Title of Class of Securities) 16385C104** (CUSIP Number) July 25, 2024 (Date of Event Which Requires Filing of this Statement) Check |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executiv |
|
| July 25, 2024 |
Exhibit 99.5 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES Chemomab Therapeutics Ltd. Warrant ADSs: Initial Exercise Date: [●], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to th |
|
| July 25, 2024 |
Exhibit 99.1 Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis First-in-Class CCL24 Neutralizing Antibody CM-101 Demonstrated a Favorable Safety Profile and Was Generally Well-Tolerated Demonstrated Anti-Fibrotic, |
|
| July 25, 2024 |
Exhibit 99.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 25, 2024, between Chemomab Therapeutics Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to |
|
| July 25, 2024 |
Exhibit 99.2 CM-101 Phase 2 SPRING TRIALPreliminary Topline Results JULY 25, 2024 NASDAQ: CMMB This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, inclu |
|
| July 25, 2024 |
Exhibit 99.4 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT, dated as of July 25, 2024 (the “Agreement”), is entered into by and among Chemomab Therapeutics Ltd., a company organized under the laws of Israel (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant |
|
| July 25, 2024 |
Chemomab Therapeutics Announces $10 Million Private Placement Exhibit 99.6 Chemomab Therapeutics Announces $10 Million Private Placement TEL AVIV, Israel — July 25, 2024 — Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or the “Company”), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it has entered into a securities purchase agreement for a private in |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executive |
|
| May 9, 2024 |
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update ─On Track for Midyear 2024 Topline Data and Late 2024/Early 2025 Open Label Data Readouts from CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PSC), Following Early Completion of Patient Enrollment Six Months Ahead of Schedule─ ─New Peer-Reviewed Publications Based on Patient Sam |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executive |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executive |
|
| May 8, 2024 |
Exhibit 99.1 Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule TEL AVIV, Israel ─ May 8, 2024 ─ Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it received formal notification from the Lis |
|
| May 3, 2024 |
Annual General Meeting of Chemomab Therapeutics Ltd. Exhibit 99.2 Annual General Meeting of Chemomab Therapeutics Ltd. Date: June 10, 2024 See Voting Instruction On Reverse Side. Please make your marks like this: ☒ Use dark black pencil or pen only For Against Abstain 1. To re-elect each of Dr. Adi Mor and Dr. Alan Moses as Class III directors, to hold office until the close of the Company’s annual general meeting of shareholders in 2027, and until |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executive |
|
| May 3, 2024 |
Exhibit 99.1 May 3, 2024 Dear Chemomab Therapeutics Ltd. Shareholders: We cordially invite you to attend the Annual General Meeting of Shareholders (the “Meeting”) of Chemomab Therapeutics Ltd. (the “Company”), to be held on June 10, 2024, at 4.30 p.m. (Israel time), at Meitar | Law Offices, located at 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel. The Company’s notice of the Meeting, |
|
| March 28, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm The Board of Directors Chemomab Therapeutics Ltd.: We consent to the incorporation by reference in the registration statement on Form F-3 (No. 333-275002) and registration statements on Form S-8 (No. 333-266868 and No. 333-259489) of our report dated March 27, 2024, with respect to the consolidated financial statements of Chemom |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SE |
|
| March 28, 2024 |
Exhibit 2.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of the date of this Annual Report on Form 20-F, Chemomab Therapeutics Ltd., an Israeli company (“we,” “our” and the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: American Depositary Sh |
|
| March 28, 2024 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14a OF THE SECURITIES EXCHANGE ACT OF 1934 AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002 I, Adi Mor, certify that: 1. I have reviewed this Annual Report on Form 20-F of Chemomab Therapeutics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mater |
|
| March 28, 2024 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14a OF THE SECURITIES EXCHANGE ACT OF 1934 AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002 I, Sigal Fattal, certify that: 1. I have reviewed this Annual Report on Form 20-F of Chemomab Therapeutics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a |
|
| March 28, 2024 |
Exhibit 13.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Sigal Fattal, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 20-F of Chemomab Therapeutics Ltd. for the fiscal year ended December 31, |
|
| March 28, 2024 |
CHEMOMAB THERAPEUTICS LTD. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Exhibit 97.1 CHEMOMAB THERAPEUTICS LTD. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Chemomab Therapeutics Ltd. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject |
|
| March 28, 2024 |
Exhibit 13.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Adi Mor, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 20-F of Chemomab Therapeutics Ltd. for the fiscal year ended December 31, 2023 |
|
| March 11, 2024 |
EX-99.1 2 ss3129663ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 3 to Schedule 13D, dated March 11, 2024 with respect to the Ordinary Shares and American Depository Shares of Chemomab Therapeutics Ltd. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exch |
|
| March 11, 2024 |
SC 13D/A 1 ss3129663sc13da.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Chemomab Therapeutics Ltd. (Name of Issuer) Ordinary Shares, no par value American Depository Shares, each of which represents twenty Ordinary Shares, no par value (Title of Class of Securities) 16385C104** |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executiv |
|
| March 7, 2024 |
Exhibit 99.1 Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update ─Accelerated Phase 2 CM-101 PSC Trial Timeline with Topline 15-Week Data Now Planned for Midyear 2024 and Topline Open Label Data Expected in Late 2024/Early 2025─ ─Cash Runway Extended through End of First Quarter 2025 as a Result of Early Completion of Phase 2 PSC Trial |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal execut |
|
| January 3, 2024 |
Exhibit 99.1 Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Mid-Year 2024 —Expected Topline Data Readout Accelerated to Mid-Year 2024 Following Early Completion of Patient Enrollment in Phase 2 Primary Sclerosing Cholangitis (PSC) SPRING Trial— —CM-101’s Unique Dual Anti-Fibrotic and Anti-Inflammat |
|
| November 15, 2023 |
EX-99.1 2 ss2718111ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 2 to Schedule 13D, dated November 14, 2023 with respect to the Ordinary Shares and American Depository Shares of Chemomab Therapeutics Ltd. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and E |
|
| November 15, 2023 |
SC 13D/A 1 ss2718111sc13da.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Chemomab Therapeutics Ltd. (Name of Issuer) Ordinary Shares, no par value American Depository Shares, each of which represents twenty Ordinary Shares, no par value (Title of Class of Securities) 16385C104** |
|
| November 9, 2023 |
Exhibit 99.2 Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update —Continued Strong Progress in Advancing CM-101 Phase 2 PSC Trial Towards Completion of Enrollment-On Track for Topline Readout in Second Half of 2024— —Reiterates Guidance that Cash Reserves Are Sufficient to Fund the Company Through the End of 2024, with Decreasing Quarterly Cash Burn E |
|
| November 9, 2023 |
Exhibit 99.1 Chemomab Therapeutics Ltd. and its subsidiaries Condensed Consolidated Interim Financial Statements As of September 30, 2023 (Unaudited) Chemomab Therapeutics Ltd. and its subsidiaries Unaudited Condensed Consolidated Interim Financial Statements as of September 30, 2023 Contents Page Condensed Consolidated Interim Balance Sheets F-3 Condensed Consolidated Interim Statements of Operat |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal execu |
|
| November 1, 2023 |
November 1, 2023 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Real Estate & Construction 100 F Street, N. |
|
| October 30, 2023 |
As filed with the Securities and Exchange Commission on October 30, 2023 As filed with the Securities and Exchange Commission on October 30, 2023 Registration No. |
|
| October 16, 2023 |
Exhibit 1.2 Chemomab Therapeutics Ltd. American Depositary Shares Each Representing 20 Ordinary Shares (no par value) Sales Agreement October 16, 2023 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Chemomab Therapeutics Ltd., a company organized under the laws of Israel (the “Company”), confirms its agreement (this “Agreement”) with Roth |
|
| October 16, 2023 |
As filed with the Securities and Exchange Commission on October 16, 2023 As filed with the Securities and Exchange Commission on October 16, 2023 Registration No. |
|
| October 16, 2023 |
Exhibit 107 CALCULATION OF FEE TABLE FORM F-3 (Form Type) CHEMOMAB THERAPEUTICS LTD. |
|
| October 16, 2023 |
CHEMOMAB THERAPEUTICS LTD. Dated as of ___________, 20___ TABLE OF CONTENTS Exhibit 4.1 CHEMOMAB THERAPEUTICS LTD. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 3 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 4 ARTICLE II. THE SECURITIES 4 Section 2.1. Issuable in Series 4 Section 2.2. Establ |
|
| August 14, 2023 |
Exhibit 99.3 Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update ─On Track to Achieve CM-101 PSC Phase 2 Readout Expected in 2H2024— ─Extended Estimated Cash Runway Through PSC Readout and 2024 Year-End─ ─Reported Positive Secondary Analysis of Data from CM-101 Phase 2 Liver Fibrosis Trial─ ─Successfully Implemented Senior Management Changes and Co |
|
| August 14, 2023 |
Exhibit 99.2 CHEMOMAB THERAPEUTICS LTD. CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS This Report on Form 6-K contains forward-looking statements. All statements other than statements of historical fact are “forward-looking statements” for purposes of this Report on Form 6-K. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, per |
|
| August 14, 2023 |
Exhibit 99.1 Chemomab Therapeutics Ltd. and its subsidiaries Condensed Consolidated Interim Financial Statements As of June 30, 2023 (Unaudited) Chemomab Therapeutics Ltd. and its subsidiaries Unaudited Condensed Consolidated Interim Financial Statements as of June 30, 2023 Contents Page Condensed Consolidated Interim Balance Sheets 3 Condensed Consolidated Interim Statements of Operations 4 Conde |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executi |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executi |
|
| July 3, 2023 |
Exhibit 99.2 Annual General Meeting of Chemomab Therapeutics Ltd. Date: August 7, 2023 See Voting Instruction On Reverse Side. Please make your marks like this: ⌧ Use dark black pencil or pen only For Against Abstain 1. To re-elect each of Dr. Claude Nicaise and Mr. Neil Cohen as Class II directors, to hold office until the close of the Company’s annual general meeting of shareholders in 2026, and |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant’s name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executive |
|
| July 3, 2023 |
Exhibit 99.1 July 3, 2023 Dear Chemomab Therapeutics Ltd. Shareholders: We cordially invite you to attend the Annual General Meeting of Shareholders (the “Meeting”) of Chemomab Therapeutics Ltd. (the “Company”), to be held on August 7, 2023 at 4:30 p.m. (Israel time), at Meitar | Law Offices, located at 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel. The Company’s notice of the Meeting |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS Empl |
|
| June 5, 2023 |
Exhibit 99.1 Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update ─Adi Mor, PhD, Co-founder, Board Director and Chief Scientific Officer, Reappointed to CEO Role─ ─Sigal Fattal, Vice President Finance, Reappointed as CFO─ ─On Track for PSC Phase 2 Topline Data Readout in Latter Part of 2024─ ─Implementing Further Reorganization and Efficiency Measures Intend |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS Emplo |
|
| June 2, 2023 |
Chemomab Therapeutics Ltd. Kiryat Atidim, Building 7 Tel Aviv, 6158002, RW 1 zk2329835.htm RW Chemomab Therapeutics Ltd. Kiryat Atidim, Building 7 Tel Aviv, 6158002, Israel +972-77-331-0156 June 2, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Chemomab Therapeutics Ltd. Request to Withdraw Registration Statement on Form S-1 File No. 333-269218 Ladies and Gentlemen: Pursuant |
|
| May 19, 2023 |
As filed with the Securities and Exchange Commission on May 19, 2023 As filed with the Securities and Exchange Commission on May 19, 2023 Registration No. |
|
| May 19, 2023 |
EX-FILING FEES 3 exhibit107.htm FILING FEES TABLE Exhibit 107 Calculation of Filing Fee Tables Form S-1/A (Form Type) CHEMOMAB THERAPEUTICS LTD. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration F |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS Emplo |
|
| May 11, 2023 |
Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update Exhibit 99.1 Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update ─Reported Top-line Results from CM-101 Phase 2 Liver Fibrosis Trial in NASH Patients Demonstrating Safety and Positive Activity Across Multiple Fibrotic and Inflammatory Biomarkers─ ─Received FDA Clearance for CM-101 Systemic Sclerosis IND—Phase 2 Trial Expected to Open Mid-year─ ─Adva |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38807 Chemomab Therapeutics Ltd. |
|
| March 22, 2023 |
As filed with the Securities and Exchange Commission on March 22, 2023 As filed with the Securities and Exchange Commission on March 22, 2023 Registration No. |
|
| March 21, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) CHEMOMAB THERAPEUTICS LTD. |
|
| March 21, 2023 |
Exhibit 4.3 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES CHEMOMAB THERAPEUTICS LTD. Warrant ADSs: [●] Initial Exercise Date: [●], 2023 Issue Date: [●], 2023 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon t |
|
| March 21, 2023 |
Form of Underwriting Agreement Exhibit 1.1 CHEMOMAB THERAPEUTICS LTD. Up to [•] American Depositary Shares Or [•] Pre-funded Warrants to Purchase American Depositary Shares And [•] Warrants to Purchase American Depositary Shares UNDERWRITING AGREEMENT [•], 2023 Aegis Capital Corp. as Representative of the several Underwriters named in Schedule I hereto 1345 Avenue of the Americas, 27th Floor New York, NY 10105 Ladies and Gentle |
|
| March 21, 2023 |
Exhibit 4.2 WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES CHEMOMAB THERAPEUTICS LTD. Warrant ADSs: [●] Initial Exercise Date: [●], 2023 Issue Date: [●], 2023 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject t |
|
| March 21, 2023 |
As filed with the Securities and Exchange Commission on March 21, 2023 As filed with the Securities and Exchange Commission on March 21, 2023 Registration No. |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-38807 (Commission file number) CHEMOMAB THER |
|
| February 22, 2023 |
As filed with the Securities and Exchange Commission on February 22, 2023 As filed with the Securities and Exchange Commission on February 22, 2023 Registration No. |
|
| February 21, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) CHEMOMAB THERAPEUTICS LTD. |
|
| February 21, 2023 |
Exhibit 4.2 CHEMOMAB THERAPEUTICS LTD. Warrant to Purchase Ordinary Shares Represented by American Depositary Shares Warrant No.: Number of American Depositary Shares: Date of Issuance: [], 2023 (“Issuance Date”) Chemomab Therapeutics Ltd., a company organized under the laws of Israel (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS |
|
| February 21, 2023 |
As filed with the Securities and Exchange Commission on February 21, 2023 As filed with the Securities and Exchange Commission on February 21, 2023 Registration No. |
|
| February 21, 2023 |
Exhibit 99.1 Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis —ABATE Phase 2 Trial Aims to Further Assess Safety and Establish Biological and Clinical Proof-of-Concept for CM-101 as a Potential Treatment for Patients with Systemic Sclerosis— TEL AVIV, Israel, February 21, 2023 - Chemomab Therapeutics, |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS |
|
| February 21, 2023 |
Exhibit 99.1 Chemomab Therapeutics Ltd. and its subsidiaries Consolidated Financial Statements As of December 31, 2022 Chemomab Therapeutics Ltd. and its subsidiaries Consolidated Financial Statements as of December 31, 2022 Contents Page Report of Independent Registered Public Accounting Firm F - 2 (PCAOB ID 1057) Consolidated Balance Sheets F - 3 Consolidated Statements of Operations F - 4 Conso |
|
| February 21, 2023 |
Form of Underwriting Agreement Exhibit 1.1 CHEMOMAB THERAPEUTICS LTD. [•] American Depositary Shares [•] Warrants UNDERWRITING AGREEMENT [•], 2023 Oppenheimer & Co. Inc. as Representative of the several Underwriters named in Schedule I hereto 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Chemomab Therapeutics Ltd., a company organized and existing under the laws of the State of Israel (the “Company”), proposes, |
|
| January 13, 2023 |
Exhibit 4.1 [EXECUTION COPY] ANCHIANO THERAPEUTICS LTD. AND THE BANK OF NEW YORK MELLON As Depositary AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Deposit Agreement Dated as of February 14, 2019 TABLE OF CONTENTS ARTICLE 1. DEFINITIONS 1 SECTION 1.1. American Depositary Shares 1 SECTION 1.2. Commission 2 SECTION 1.3. Company 2 SECTION 1.4. Custodian 2 SECTION 1.5. Delisting Event 2 SECTION |
|
| January 13, 2023 |
As filed with the Securities and Exchange Commission on January 13, 2023 As filed with the Securities and Exchange Commission on January 13, 2023 Registration No. |
|
| January 13, 2023 |
Exhibit 10.9 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered between Chemomab Therapeutics, Inc. (the “Company”), a Delaware corporation, and Dale Pfost (the “Executive”), as of September 1, 2021 (the “Effective Date”). The Company is a wholly-owned subsidiary of Chemomab Therapeutics Ltd., an Israeli company and the parent company of the Company (t |
|
| January 13, 2023 |
Exhibit 10.10 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered between Chemomab Therapeutics, Inc. (the “Company”), a Delaware corporation, and Donald Marvin (the “Executive”), as of November 8, 2021 (the “Effective Date”). The Company is a wholly-owned subsidiary of Chemomab Therapeutics Ltd., an Israeli company and the parent company of the Company |
|
| January 13, 2023 |
Exhibit 10.11 CONSULTING AGREEMENT THIS AGREEMENT (the “Agreement”) is made on this 18 of April, 2022 between ChemomAb Ltd., a private company number 514694991, whose address is at Kiryat Atidim, Building 7, Tel-Aviv, Israel (the “Company”) and Prof. Kobi George and Dr. Adi Mor LTD, a private company number 515520542, whose address is at 15 Kafrisin St., Tel-Aviv Israel (the “Consultant”) and Dr. |
|
| January 13, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) CHEMOMAB THERAPEUTICS LTD. |
|
| January 13, 2023 |
Exhibit 21.1 Chemomab Therapeutics Ltd. List of Subsidiaries Name Jurisdiction of Incorporation % Ownership Chemomab Ltd. Israel 100 % Chemomab Therapeutics, Inc. Delaware 100 % Chemomab Therapeutics Israel Ltd. Israel 100 % |
|
| January 11, 2023 |
Corporate Presentation of Chemomab Therapeutics Ltd. (furnished herewith) Exhibit 99.1 |
|
| January 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS E |
|
| January 5, 2023 |
SC 13D/A 1 ss1648370sc13da.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Chemomab Therapeutics Ltd. (Name of Issuer) Ordinary Shares, no par value American Depository Shares, each of which represents twenty Ordinary Shares, no par value (Title of Class of Securities) 16385C104** ( |
|
| January 5, 2023 |
EX-99.1 2 ss1648370ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated January 3, 2023 with respect to the Ordinary Shares and American Depository Shares of Chemomab Therapeutics Ltd. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and |
|
| January 3, 2023 |
Exhibit 99.1 Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients ?CM-101 Met Primary Endpoint of Safety and Tolerability and Showed Positive Activity Across Multiple Liver Fibrosis Biomarkers and Physiologic Assessments? TEL AVIV, Israel, January 3, 2023 - Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology compan |
|
| January 3, 2023 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS Employer of Inco |
|
| November 29, 2022 |
Exhibit 10.1 Chemomab Therapeutics, Ltd. Kiryat Atidim, Building 7 Tele Aviv, Israel 6158002 Date: October 10, 2022 Matt Frankel 672 Prospect Avenue Princeton, New Jersey 08540 Dear Matt: Chemomab Therapeutics, Inc. (the “Company”) is pleased to offer you employment as Chief Medical Officer & VP, Drug Development on the following terms: 1. Position; Effective Date. You will report to the Chairman |
|
| November 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 (November 14, 2022) Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State o |
|
| November 17, 2022 |
IL:CMMB / Chemomab Therapeutics Ltd / Mor George Adi - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 240.13d-2(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) (Amendment No. 1)* Chemomab Therapeutics Ltd. (Name of Issuer) American Depositary Shares, each of which represents twenty Ordinary Shares, no par value Ordinary |
|
| November 17, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned parties hereby agree that this Amendment No. |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2022 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS |
|
| November 14, 2022 |
Chemomab Announces Appointment of Matthew Frankel, MD, MBA as Chief Medical Officer Exhibit 99.1 Chemomab Announces Appointment of Matthew Frankel, MD, MBA as Chief Medical Officer TEL AVIV, Israel, November 14, 2022 - Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the appointment of Matthew |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38807 Chemomab Therapeutics Ltd. |
|
| August 15, 2022 |
As filed with the Securities and Exchange Commission on August 15, 2022 As filed with the Securities and Exchange Commission on August 15, 2022 Registration No. |
|
| August 15, 2022 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) CHEMOMAB THERAPEUTICS LTD. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2017 Equity-Based |
|
| August 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS Em |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38807 Chemomab Therapeutics Ltd. |
|
| August 12, 2022 |
Exhibit 99.1 Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update ?Chemomab to Host Webcast and Conference Call for Investors Today, August 12 at 8:00 am ET? TEL AVIV, Israel, August 12, 2022 - Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibr |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS Empl |
|
| June 21, 2022 |
Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors Exhibit 99.1 Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors ?Ms. Quigley?s Broad Biotechnology Industry Experience Encompasses Leadership Positions in Executive Management, Operations and Legal Affairs? TEL AVIV, Israel, June 21, 2022 - Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and developme |
|
| June 8, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS Emplo |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS Emplo |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS Emplo |
|
| May 12, 2022 |
Exhibit 99.1 Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update ?Company to Host Conference Call for Investors Today, May 12 at 8:00 am ET? TEL AVIV, Israel, May 12, 2022 - Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory disease |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38807 Chemomab Therapeutics Ltd. |
|
| April 28, 2022 |
DEF 14A 1 zk2227688.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Onl |
|
| April 25, 2022 |
Up to $18,125,000 American Depositary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-255658 PROSPECTUS SUPPLEMENT (To Prospectus dated May 17, 2021) Up to $18,125,000 American Depositary Shares We have entered into a Controlled Equity OfferingSM Sales Agreement (the ?sales agreement?) with Cantor Fitzgerald & Co., (?Cantor Fitzgerald?) or (the ?Sales Agent?), relating to our American Depositary Shares, each representing twenty |
|
| March 30, 2022 |
, 2021, by and between Chemomab Therapeutics, Inc. and Donald Marvin Exhibit 10.11 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is entered between Chemomab Therapeutics, Inc. (the ?Company?), a Delaware corporation, and Donald Marvin (the ?Executive?), as of November 8, 2021 (the ?Effective Date?). The Company is a wholly-owned subsidiary of Chemomab Therapeutics Ltd., an Israeli company and the parent company of the Company |
|
| March 30, 2022 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of the date of this Annual Report on Form 10-K, Chemomab Therapeutics Ltd., an Israeli company (?we,? ?our? and the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: American Depositary Sh |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-38807 (Commission file number) CHEMOMAB THER |
|
| March 30, 2022 |
, 2021, by and between Chemomab Therapeutics, Inc. and Dale Pfost Exhibit 10.10 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is entered between Chemomab Therapeutics, Inc. (the ?Company?), a Delaware corporation, and Dale Pfost (the ?Executive?), as of September 1, 2021 (the ?Effective Date?). The Company is a wholly-owned subsidiary of Chemomab Therapeutics Ltd., an Israeli company and the parent company of the Company ( |
|
| March 30, 2022 |
Exhibit 21.1 Chemomab Therapeutics Ltd. List of Subsidiaries Name Jurisdiction of Incorporation % Ownership Chemomab Ltd. Israel 100 % Chemomab Therapeutics, Inc. Delaware 100 % Chemomab Therapeutics Israel Ltd. Israel 100 % |
|
| March 30, 2022 |
Exhibit 10.2 COMPENSATION POLICY CHEMOMAB THERAPEUTICS LTD. Compensation Policy for Executive Officers and Directors (As Adopted on July 19, 2021) A. Overview and Objectives 1. Introduction This document sets forth the Compensation Policy for Executive Officers and Directors (this ?Compensation Policy? or ?Policy?) of Chemomab Therapeutics Ltd. (?Chemomab? or the ?Company?), in accordance with the |
|
| March 9, 2022 |
Exhibit 99.1 Chemomab Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update ?Company Announces Revisions Intended to Optimize CM-101 Clinical Development Program and Produce More Informative Data, More Rapidly and Efficiently; Changes Also Expected to Extend Cash Runway through End of 2023? ?Company to Host Conference Call for Investors Today, Ma |
|
| March 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2022 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS Empl |
|
| February 11, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2022 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS |
|
| February 10, 2022 |
IL:CMMB / Chemomab Therapeutics Ltd / Gabriel Capital Management Ltd. - SC 13G/A Passive Investment SC 13G/A 1 chemomabsc13gadec312021.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Chemomab therapeutics ltd. (Name of Issuer) ORDINARY SHARES, NO PAR VALUE (Title of Class of Securities) 16385C104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Ch |
|
| January 20, 2022 |
Joint Filing Agreement pursuant to Rule 13d-1(k)(1) Exhibit 1 JOINT FILING AGREEMENT The undersigned parties hereby agree that this Schedule 13D filed herewith relating to the American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share of Chemomab Therapeutics Ltd. |
|
| January 20, 2022 |
IL:CMMB / Chemomab Therapeutics Ltd / Mor George Adi - SC 13D Activist Investment SC 13D 1 zk2227076.htm SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 240.13d-2(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) (Amendment No. )* Chemomab Therapeutics Ltd. (Name of Issuer) American Depositary Shares, each of which represents twenty Ordinary |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| December 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS |
|
| December 16, 2021 |
Chemomab Therapeutics Announces Expected Appointment of Dale R. Pfost as Chairman of the Board Exhibit 99.1 Chemomab Therapeutics Announces Expected Appointment of Dale R. Pfost as Chairman of the Board TEL AVIV, Israel, December 16, 2021. - Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that, as planne |
|
| December 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2021 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS E |
|
| December 3, 2021 |
Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer Dr. Weiner Brings Chemomab Extensive Biotechnology and Pharmaceutical Industry R&D and Strategic Experience, Including Overseeing the Design and Management of Clinical Trials for Rare and Challenging Therapeutic Indications Appointment Follows Resignation of Current |
|
| November 12, 2021 |
Exhibit 99.1 Chemomab Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update -Expands Senior Management Team While Advancing Two Independent Phase 2 Trials and Preparing to Initiate a Third in Early 2022- TEL AVIV, Israel, November 12, 2021 - Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), (Chemomab) a clinical-stage biotech company focused on the discovery and dev |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38807 Chemomab Therapeutics Ltd. |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdicti |
|
| November 10, 2021 |
Exhibit 99.1 Pioneering Innovative Treatments for Fibrotic DiseasesCorporate Overview | Non-Confidential | November 2021 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; |
|
| November 10, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS E |
|
| November 8, 2021 |
Exhibit 99.1 Chemomab Therapeutics Names Donald R. Marvin Chief Financial Officer, Executive Vice President and Chief Operating Officer Seasoned veteran brings Chemomab three decades of diverse life sciences industry experience TEL AVIV, Israel, November 8, 2021 - Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) a clinical-stage biotech company focused on the discovery and development of inno |
|
| November 3, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS E |
|
| November 3, 2021 |
Chemomab Therapeutics Systemic Sclerosis Live WebinarNovember 3, 2021 Exhibit 99.1 Chemomab Therapeutics Systemic Sclerosis Live WebinarNovember 3, 2021 This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; the future operations of Chemomab and its ability to successfully |
|
| October 26, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2021 (October 25, 2021) Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction |
|
| October 25, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2021 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS E |
|
| October 25, 2021 |
Exhibit 99.1 Pioneering Innovative Treatments for Fibrotic DiseasesCorporate Overview | Non-Confidential | October 2021 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; t |
|
| September 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| September 13, 2021 |
As filed with the Securities and Exchange Commission on September 13, 2021 As filed with the Securities and Exchange Commission on September 13, 2021 Registration No. |
|
| September 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| September 2, 2021 |
Exhibit 99.2 Pioneering Innovative Treatments for Fibrotic DiseasesCorporate Overview | Non-Confidential | September 2021 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; |
|
| September 2, 2021 |
Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer Exhibit 99.1 Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer Dr. Adi Mor continues as Chief Scientific Officer, directing scientific strategy and overseeing R&D operations TEL AVIV, Israel, September 2, 2021 - Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for infla |
|
| September 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2021 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS |
|
| August 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2021 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS Em |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38807 Chemomab Therapeutics Ltd. |
|
| August 13, 2021 |
Chemomab Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update Exhibit 99.1 Chemomab Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update ? CM-101 Phase 2a trials in PSC and liver fibrosis continue to enroll patients with data Expected in 2022 ? ? Cash and equivalents of $67 million as of June 30, 2021, expected to fund current operating plan through mid 2023 ? TEL-AVIV, Israel, August 13, 2021 (NEWSWIRE) - Chemomab Ther |
|
| July 22, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2021 (July 19, 2021) Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Comm |
|
| June 14, 2021 |
DEF 14A 1 zk2126186.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| June 1, 2021 |
PRE 14A 1 zk2126131.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| May 13, 2021 |
Exhibit 99,1 Chemomab Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update Announced positive data from its Phase Ib SPARK study evaluating CM-101 in NAFLD patients Announced first patient enrolled in two Phase IIa studies of CM-101 Completed merger with Anchiano Therapeutics, and began trading on the Nasdaq Exchange under the ticker CMMB Cash position of $58. |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Other Jurisdiction (Commission (IRS Emplo |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38807 Chemomab Therapeutics Ltd. |
|
| May 12, 2021 |
May 12, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Jane Park Re: Chemomab Therapeutics Ltd. Registration Statement on Form S-3 Filed April 30, 2021 File No. 333-255658 Acceleration Request Requested Date: May 17, 2021 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: In accordance |
|
| April 30, 2021 |
As filed with the Securities and Exchange Commission on April 30, 2021 Registration No. |
|
| April 30, 2021 |
Exhibit 1.2 Chemomab Therapeutics Ltd. American Depositary Shares Each Representing 20 Ordinary Shares (no par value) Controlled Equity OfferingSM Sales Agreement April 30, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Chemomab Therapeutics Ltd. a company organized under the laws of Israel (the ?Company?), confirms its agreement (this ?Agreement?) with Canto |
|
| April 30, 2021 |
Form of Indenture between the Registrant and one or more trustees to be named Exhibit 4.2 CHEMOMAB THERAPEUTICS LTD., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities Table of contents Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities. 5 Section 2.02 Form of Securities and Trustee?s Certificate. |
|
| April 29, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-255249 PROSPECTUS 6,951,292 American Depositary Shares Representing 139,025,840 Ordinary Shares Warrants to purchase 261,929 American Depositary Shares Representing 5,238,580 Ordinary Shares Chemomab Therapeutics Ltd. This prospectus relates to the proposed resale from time to time of up to 7,213,221 ADSs, each representing 20 Ordinary Shares, |
|
| April 26, 2021 |
April 26, 2021 Securities and Exchange Commission Division of Corporation Finance 100 F Street N. |
|
| April 15, 2021 |
Registration Rights Agreement, dated December 14, 2020 Exhibit 10.3 ANCHIANO THERAPEUTICS LTD./ CHEMOMAB LTD. REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of this 14 day of December 2020, with effectiveness as of the Effective Date (as defined below), by and among (i) Anchiano Therapeutics Ltd., an Israeli company, which will change its name to Chemomab Therapeutics Ltd. upon the Effec |
|
| April 15, 2021 |
As filed with the Securities and Exchange Commission on April 15, 2021 Registration No. |
|
| April 15, 2021 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Chemomab Therapeutics Ltd. (Name of Issuer) Ordinary Shares, no par value American Depositary Shares, each of which represents twenty Ordinary Shares, no par value, evidenced by American Depositary Receipts (Title of Class of Securities) 16385C1 |
|
| April 15, 2021 |
Exhibit 99.9 Joint Filing Agreement The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accurac |
|
| April 14, 2021 |
UNAUDITED PRO FORMA Condensed COMBINED FINANCIAL STATEMENTS Exhibit 99.1 UNAUDITED PRO FORMA Condensed COMBINED FINANCIAL STATEMENTS On March 16, 2021, pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated as of December 14, 2020, by and among Anchiano Therapeutics Ltd. (“Anchiano”), CMB Acquisition Ltd., an Israeli limited company and wholly-owned subsidiary of Anchiano (“Merger Sub”), and Chemomab Ltd., an Israeli limited company ( |
|
| April 14, 2021 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2021 (March 17, 2021) Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel 001-38807 81-3676773 (State or Othe |
|
| April 5, 2021 |
FIRST AMENDMENT TO ASSET PURCHASE AND ASSIGNMENT AGREEMENT Exhibit 99.1 FIRST AMENDMENT TO ASSET PURCHASE AND ASSIGNMENT AGREEMENT THIS FIRST AMENDMENT TO ASSET PURCHASE AND ASSIGNMENT AGREEMENT (the ?Amendment?), is made effective as of the 31th day of March, 2021 (the ?Amendment Date?) by and between Anchiano Therapeutics, Inc., a company organized under the laws of Delaware (?Anchiano?) and Kestrel Therapeutics, Inc., a company organized under the laws |
|
| April 5, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2021 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel (State or Other Jurisdiction of Incorporation) 001-38807 (Commission Fi |
|
| March 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Chemomab Therapeutics Ltd. (Name of Issuer) Ordinary Shares, no par value American Depositary Shares, each of which represents twenty Ordinary Shares, no par value (Title of Class of Securities) 16385C104** (CUSIP Number) OrbiMed Israel BioFund GP Limited Partnership OrbiM |
|
| March 26, 2021 |
EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated March 26, 2021 (the “Schedule 13D”), with respect to the Shares of Chemomab Therapeutics Ltd. |
|
| March 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Chemomab Therapeutics Ltd. (Name of Issuer) Ordinary Shares, no par value per share (Title of Class of Securities) 16385C104** (CUSIP Number) March 16, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| March 19, 2021 |
Chemomab Ltd. Financial Statements As at December 31, 2020 Exhibit 99.1 Chemomab Ltd. Financial Statements As at December 31, 2020 Chemomab Ltd. Financial Statements as of December 31, 2020 Contents Page Report of Independent Registered Public Accounting Firm 2 Balance Sheets 3 Statements of Operations 4 Statements of Changes in Equity 5 Statements of Cash Flows 6 Notes to the Financial Statements 7-24 Somekh Chaikin 17 Ha’arba’a Street, PO Box 609 KPMG M |
|
| March 19, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2021 (March 17, 2021) Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel (State or Other Jurisdiction of Incorporation) 001- |
|
| March 17, 2021 |
Form of American Depositary Shares Purchase Warrant of Chemomab Therapeutics Ltd. Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| March 17, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March [], 2021, between Anchiano Therapeutics Ltd., a company organized under the laws of Israel (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, on Decemb |
|
| March 17, 2021 |
Exhibit 99.2 Chemomab Completes Merger with Anchiano Therapeutics Shares of Chemomab Therapeutics to commence trading on the Nasdaq Capital Market on March 17, 2021 under the new ticker symbol “CMMB” Combined company will focus on advancing Chemomab’s CM-101 currently in Phase 2 for rare fibrotic indications Company to receive gross proceeds of $45.5 million from a PIPE financing, led by healthcar |
|
| March 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2021 Chemomab Therapeutics Ltd. (Exact name of Registrant as Specified in Its Charter) State of Israel (State or Other Jurisdiction of Incorporation) 001-38807 (Commission F |
|
| March 17, 2021 |
Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| March 17, 2021 |
Exhibit 10.4 ASSET PURCHASE AND ASSIGNMENT AGREEMENT This ASSET PURCHASE AND ASSIGNMENT AGREEMENT (this ?Agreement?), dated as of March 16, 2021, is made between Anchiano Therapeutics, Inc., a company organized under the laws of Delaware (?Anchiano?) and Kestrel Therapeutics, Inc., a company organized under the laws of Delaware (?Kestrel?; each of Anchiano and Kestrel, a ?Party? and, together, the |
|
| March 17, 2021 |
Exhibit 99.1 Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing Anchiano shareholders approve all resolutions at shareholder meeting The merged company is expected to receive approximate gross proceeds from the private financing of $45.5 million, which will be used to advance the Chemomab pipeline TEL-AVIV, Israel, March 15, 2021 (NEWSWIRE) - An |
|
| March 17, 2021 |
Exhibit 3.1 THE COMPANIES LAW, 1999 A LIMITED LIABILITY COMPANY - ARTICLES OF ASSOCIATION OF CHEMOMAB THERAPEUTICS LTD. Therapeutics As Adopted on , 2021 Preliminary 1. Definitions; Interpretation. (a) In these Articles, the following terms (whether or not capitalized) shall bear the meanings set forth opposite them, respectively, unless the subject or context requires otherwise. ?Articles? shall |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2021 ANCHIANO THERAPEUTICS LTD. (Exact name of registrant as specified in its charter) State of Israel 001-38807 81-3676773 (State or other jurisdiction of incorporation) (Co |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2021 ANCHIANO THERAPEUTICS LTD. (Exact name of registrant as specified in its charter) State of Israel 001-38807 81-3676773 (State or other jurisdiction of incorporation) (Co |
|
| March 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITI |
|
| March 9, 2021 |
List of Subsidiaries (filed herewith). Exhibit 21.1 Anchiano Therapeutics Ltd. List of Subsidiaries Name Jurisdiction of Incorporation Parent % Ownership Anchiano Therapeutics Israel Ltd. Israel Anchiano Therapeutics Ltd. 100 % Anchiano Therapeutics, Inc. Delaware Anchiano Therapeutics Israel Ltd. 100 % |
|
| March 9, 2021 |
Filed by Anchiano Therapeutics Ltd. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Chemomab Ltd. Pioneering Innovative Treatments Corporate Overview | Non-Confidential for Fibrotic Diseases Global Life Sciences March 9-10, 2021 Conference Forward Looking Statements Th |
|
| February 12, 2021 |
PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(3)? ?Registration No. 333-252070? PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Shareholders of Anchiano Therapeutics Ltd.: You are cordially invited to attend a special meeting of the shareholders of Anchiano Therapeutics Ltd., an Israeli limited company, which we refer to as ?we,? ?Anchiano,? or the ?Company,? which will be held at 4:30 p.m., |
|
| February 10, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 10, 2021 Registration No. |
|
| February 10, 2021 |
CORRESP 1 filename1.htm ANCHIANO THERAPEUTICS LTD. February 10, 2021 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Acceleration Request of Anchiano Therapeutics Ltd. Registration Statement on Form S-4, as amended Filed on January 13, 2021 (File No. 333-252070) Ladies and Gentlemen: In accordance with Rule 46 |
|
| February 10, 2021 |
Consent of Adi Mor to be named as a director. Exhibit 99.4 January 13, 2021 Anchiano Therapeutics Ltd. One Kendall Square Building 1400E Suite 14-105 Cambridge, MA 02139 Consent to Reference in Proxy Statement/Prospectus Anchiano Therapeutics Ltd. (the “Company”) has filed a Registration Statement on Form S-4 (Registration No. 333-252070) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities |
|
| February 10, 2021 |
Consent of Claude Nicaise to be named as a director EX-99.9 10 tm211883d5ex99-9.htm EXHIBIT 99.9 Exhibit 99.9 February 9, 2021 Anchiano Therapeutics Ltd. One Kendall Square Building 1400E Suite 14-105 Cambridge, MA 02139 Consent to Reference in Proxy Statement/Prospectus Anchiano Therapeutics Ltd. (the “Company”) has filed a Registration Statement on Form S-4 (Registration No. 333-252070) with the Securities and Exchange Commission under the Securi |
|
| February 10, 2021 |
Form of Proxy Card for Special Meeting of Shareholders of Anchiano Therapeutics Ltd. EX-99.1 4 tm211883d5ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Extraordinary General Meeting of Anchiano Therapeutics Ltd. to be held on March 15, 2021 For Holders as of February 5, 2021 Extraordinary General Meeting of Anchiano Therapeutics Ltd. March 15, 2021 See Voting Instruction On Reverse Side. Date: Please make your marks like this: Use pen only For Against Abstain (1) to approve the consummati |
|
| February 10, 2021 |
Consent of Joel Maryles to be named as a director Exhibit 99.7 February 9, 2021 Anchiano Therapeutics Ltd. One Kendall Square Building 1400E Suite 14-105 Cambridge, MA 02139 Consent to Reference in Proxy Statement/Prospectus Anchiano Therapeutics Ltd. (the “Company”) has filed a Registration Statement on Form S-4 (Registration No. 333-252070) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities |
|
| February 10, 2021 |
Consent of Stephen Squinto to be named as a director Exhibit 99.5 February 9, 2021 Anchiano Therapeutics Ltd. One Kendall Square Building 1400E Suite 14-105 Cambridge, MA 02139 Consent to Reference in Proxy Statement/Prospectus Anchiano Therapeutics Ltd. (the “Company”) has filed a Registration Statement on Form S-4 (Registration No. 333-252070) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities |
|
| February 10, 2021 |
CORRESP 1 filename1.htm ANCHIANO THERAPEUTICS LTD. February 10, 2021 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Acceleration Request of Anchiano Therapeutics Ltd. Registration Statement on Form S-4, as amended Filed on January 13, 2021 (File No. 333-252070) Ladies and Gentlemen: In accordance with Rule 46 |
